Janelle C. Waite

TL;DR: The biology of Th17 cells, their role in autoimmune disease development, and in AOSD in particular, are discussed, as well as the growing interest of the pharmaceutical industry in their use as therapeutic targets.

TL;DR: This combination immunotherapy led to a synergistic increase in tumor antigen–specific memory precursor effector T cells dependent on availability of the CD226 costimulatory pathway and provided a mechanistic rationale for conducting further clinical trials of combined anti-GITR and anti–PD-1 immunotherapy in human cancer.

TL;DR: The preclinical characterization of REGN2810 is described, a fully human hinge-stabilized IgG4(S228P) high-affinity anti–PD-1 antibody that potently blocks PD-1 interactions with PD-L1 andPD-L2, validating it as a potent and promising candidate for cancer immunotherapy.

TL;DR: A critical role for Id1 is revealed in suppressing the anti-tumour immune response during tumour progression and metastasis by downregulation of key molecules involved in DC differentiation and suppression of CD8 T-cell proliferation, thus promoting primary tumour growth and metastatic progression.

TL;DR: Unlike CD28 superagonists, which broadly activate T cells and resulted in profound toxicity in early clinical trials, these TSAxCD28 bispecifics show limited activity and no toxicity when used alone in genetically humanized immunocompetent mouse models or in primates.